Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness

This study has been terminated.
Information provided by:
Spectrum Pharmaceuticals, Inc Identifier:
First received: July 19, 2004
Last updated: March 27, 2014
Last verified: March 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2005
  Estimated Primary Completion Date: No date given